Objective To systematically evaluate the efficacy of telemedicine on patients with chronic heart failure. Methods We performed a computerized search of Web of Science, Embase, PubMed, Cochrane Library, China Biomedical Database (SinoMed), CNKI, Wanfang, and VIP databases for studies regarding telemedicine interventions for patients with chronic heart failure from their inception to November 5, 2025. Two reviewers independently conducted study screening, and data extraction. Risk of bias assessment for the included studies was performed using the Cochrane ROB 2.0 tool. Meta-analysis was performed using Review Manager 5.3 and Stata 17.0 software. Results A total of 39 randomized controlled trials (RCTs) involving 13 979 patients were included. All studies were rated as Grade A or B. The meta-analysis results showed that the intervention group had significantly lower rates of all-cause readmission [OR=0.63, 95%CI (0.50, 0.80), P<0.001], heart failure-related readmission [OR=0.50, 95%CI (0.38, 0.64), P<0.001], cardiovascular-related readmission [OR=0.55, 95%CI (0.38, 0.79), P=0.001], and heart failure-related mortality [OR=0.69, 95%CI (0.55, 0.88), P=0.003] compared to the control group. The quality of life [SMD=–1.05, 95%CI (–1.61, –0.49), P<0.001] and self-care ability [SMD=–1.53, 95%CI (–2.19, –0.86), P<0.001] in the intervention group were significantly better than those in the control group. There was no statistically significant difference in all-cause mortality between the two groups (P>0.05). Conclusion Telemedicine interventions can effectively reduce readmission rates and heart failure-related mortality in patients with chronic heart failure and have a positive effect on improving their quality of life and self-care ability. However, it has no significant effect on all-cause mortality. More large-sample RCTs with long-term follow-up are needed to further validate the impact of telemedicine on all-cause mortality in patients with heart failure.
Objective To observe the effectiveness of IMPACT management mode on self-care and management abilities of breast cancer patients undergoing chemotherapy with implantable venous access port (VAP). Methods Breast cancer patients who underwent chemotherapy with VAP at Shangjin Hospital, West China Hospital, Sichuan University between March 2020 and June 2021 were prospectively included. IMPACT mode was used for self-management training guidance. The patient self-care abilities before training and at 1 month, 2 months, and 3 months of training were compared, and the patient self-management abilities at 1 month and 3 months of training were compared. Results A total of 74 patients with breast cancer undergoing chemotherapy with VAP were included. The total score of self-care ability of patients before training and at 1 month, 2 months, and 3 months of training was 112.11±14.63, 123.20±15.73, 127.95±13.89, and 131.92±13.60, respectively, and all the between-time-point differences were statistically significant (P<0.05). In terms of self-concept score, all the between-time-point differences were statistically significant (P<0.05) with increasing score over time, except the difference between the score at 3 months of training and that at 2 months of training (P>0.05). In terms of self-responsibility and self-care skill scores, all the between-time-point differences were statistically significant (P<0.05) with increasing scores over time, except the difference between the score at 2 months of training and that at 1 month of training (P>0.05). In terms of health knowledge level, the scores at 1 month, 2 months, and 3 months of training were higher than that before training (P<0.05), and the score at 3 months of training was higher than that at 1 month of training (P<0.05). The self-management ability scores in all dimensions at 3 months of training were higher than those at 1 month of training, and the differences were statistically significant (P<0.05). Conclusion The IMPACT management mode can effectively improve the self-care and management abilities of breast cancer patients undergoing chemotherapy with VAP, thereby ensuring the normal use of VAP, reducing the occurrence of complications, and reducing the burden on families and society.